Leptin signals via TGFB1 to promote metastatic potential and stemness in breast cancer

Ameet K. Mishra, Christopher R. Parish, Ma Li Wong, Julio Licinio, Anneke C. Blackburn

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Epidemiological studies have shown obesity to be linked with poorer outcomes in breast cancer patients. The molecular mechanisms responsible for the increased risk of invasive/metastatic disease with obesity are complex, but may include elevated levels of adipokines such as leptin. Using physiological levels of leptin found in obesity in a novel chronic in vitro treatment model (≤200 ng/ml for 14 days), we confirmed the occurrence of leptin-mediated changes in growth, apoptosis and metastatic behavior, and gene expression changes representing epithelial-to-mesenchymal transition (EMT) and a cancer stem cell (CSC) like phenotype in breast epithelial and cancer cell lines (MCF10A, MCF10AT1, MCF7 and MDAMB-231). Further, we have discovered that these effects were accompanied by increased expression of TGFB1, and could be significantly reduced by co-treatment with neutralizing antibody against TGFB1, indicating that the induction of these characteristics was mediated via TGFB1. Occurring in both MCF7 and MCF10AT1 cells, it suggests these actions of leptin to be independent of estrogen receptor status. By linking leptin signalling to the established TGFB1 pathway of metastasis/EMT, this study gives a direct mechanism by which leptin can contribute to the poorer outcomes of obese cancer patients. Inhibitors of TGFB1 are in currently in phase III clinical trials in other malignancies, thus identifying the connection between leptin and TGFB1 will open new therapeutic opportunities for improving outcomes for obese breast cancer patients.

LanguageEnglish
Article numbere0178454
JournalPLoS ONE
Volume12
Issue number5
DOIs
Publication statusPublished - 1 May 2017

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Mishra, A. K., Parish, C. R., Wong, M. L., Licinio, J., & Blackburn, A. C. (2017). Leptin signals via TGFB1 to promote metastatic potential and stemness in breast cancer. PLoS ONE, 12(5), [e0178454]. https://doi.org/10.1371/journal.pone.0178454
Mishra, Ameet K. ; Parish, Christopher R. ; Wong, Ma Li ; Licinio, Julio ; Blackburn, Anneke C. / Leptin signals via TGFB1 to promote metastatic potential and stemness in breast cancer. In: PLoS ONE. 2017 ; Vol. 12, No. 5.
@article{7dd4f7980e724b08b1dfeeaf6a48ae1d,
title = "Leptin signals via TGFB1 to promote metastatic potential and stemness in breast cancer",
abstract = "Epidemiological studies have shown obesity to be linked with poorer outcomes in breast cancer patients. The molecular mechanisms responsible for the increased risk of invasive/metastatic disease with obesity are complex, but may include elevated levels of adipokines such as leptin. Using physiological levels of leptin found in obesity in a novel chronic in vitro treatment model (≤200 ng/ml for 14 days), we confirmed the occurrence of leptin-mediated changes in growth, apoptosis and metastatic behavior, and gene expression changes representing epithelial-to-mesenchymal transition (EMT) and a cancer stem cell (CSC) like phenotype in breast epithelial and cancer cell lines (MCF10A, MCF10AT1, MCF7 and MDAMB-231). Further, we have discovered that these effects were accompanied by increased expression of TGFB1, and could be significantly reduced by co-treatment with neutralizing antibody against TGFB1, indicating that the induction of these characteristics was mediated via TGFB1. Occurring in both MCF7 and MCF10AT1 cells, it suggests these actions of leptin to be independent of estrogen receptor status. By linking leptin signalling to the established TGFB1 pathway of metastasis/EMT, this study gives a direct mechanism by which leptin can contribute to the poorer outcomes of obese cancer patients. Inhibitors of TGFB1 are in currently in phase III clinical trials in other malignancies, thus identifying the connection between leptin and TGFB1 will open new therapeutic opportunities for improving outcomes for obese breast cancer patients.",
author = "Mishra, {Ameet K.} and Parish, {Christopher R.} and Wong, {Ma Li} and Julio Licinio and Blackburn, {Anneke C.}",
year = "2017",
month = "5",
day = "1",
doi = "10.1371/journal.pone.0178454",
language = "English",
volume = "12",
journal = "PLoS ONE",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "5",

}

Mishra, AK, Parish, CR, Wong, ML, Licinio, J & Blackburn, AC 2017, 'Leptin signals via TGFB1 to promote metastatic potential and stemness in breast cancer', PLoS ONE, vol. 12, no. 5, e0178454. https://doi.org/10.1371/journal.pone.0178454

Leptin signals via TGFB1 to promote metastatic potential and stemness in breast cancer. / Mishra, Ameet K.; Parish, Christopher R.; Wong, Ma Li; Licinio, Julio; Blackburn, Anneke C.

In: PLoS ONE, Vol. 12, No. 5, e0178454, 01.05.2017.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Leptin signals via TGFB1 to promote metastatic potential and stemness in breast cancer

AU - Mishra, Ameet K.

AU - Parish, Christopher R.

AU - Wong, Ma Li

AU - Licinio, Julio

AU - Blackburn, Anneke C.

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Epidemiological studies have shown obesity to be linked with poorer outcomes in breast cancer patients. The molecular mechanisms responsible for the increased risk of invasive/metastatic disease with obesity are complex, but may include elevated levels of adipokines such as leptin. Using physiological levels of leptin found in obesity in a novel chronic in vitro treatment model (≤200 ng/ml for 14 days), we confirmed the occurrence of leptin-mediated changes in growth, apoptosis and metastatic behavior, and gene expression changes representing epithelial-to-mesenchymal transition (EMT) and a cancer stem cell (CSC) like phenotype in breast epithelial and cancer cell lines (MCF10A, MCF10AT1, MCF7 and MDAMB-231). Further, we have discovered that these effects were accompanied by increased expression of TGFB1, and could be significantly reduced by co-treatment with neutralizing antibody against TGFB1, indicating that the induction of these characteristics was mediated via TGFB1. Occurring in both MCF7 and MCF10AT1 cells, it suggests these actions of leptin to be independent of estrogen receptor status. By linking leptin signalling to the established TGFB1 pathway of metastasis/EMT, this study gives a direct mechanism by which leptin can contribute to the poorer outcomes of obese cancer patients. Inhibitors of TGFB1 are in currently in phase III clinical trials in other malignancies, thus identifying the connection between leptin and TGFB1 will open new therapeutic opportunities for improving outcomes for obese breast cancer patients.

AB - Epidemiological studies have shown obesity to be linked with poorer outcomes in breast cancer patients. The molecular mechanisms responsible for the increased risk of invasive/metastatic disease with obesity are complex, but may include elevated levels of adipokines such as leptin. Using physiological levels of leptin found in obesity in a novel chronic in vitro treatment model (≤200 ng/ml for 14 days), we confirmed the occurrence of leptin-mediated changes in growth, apoptosis and metastatic behavior, and gene expression changes representing epithelial-to-mesenchymal transition (EMT) and a cancer stem cell (CSC) like phenotype in breast epithelial and cancer cell lines (MCF10A, MCF10AT1, MCF7 and MDAMB-231). Further, we have discovered that these effects were accompanied by increased expression of TGFB1, and could be significantly reduced by co-treatment with neutralizing antibody against TGFB1, indicating that the induction of these characteristics was mediated via TGFB1. Occurring in both MCF7 and MCF10AT1 cells, it suggests these actions of leptin to be independent of estrogen receptor status. By linking leptin signalling to the established TGFB1 pathway of metastasis/EMT, this study gives a direct mechanism by which leptin can contribute to the poorer outcomes of obese cancer patients. Inhibitors of TGFB1 are in currently in phase III clinical trials in other malignancies, thus identifying the connection between leptin and TGFB1 will open new therapeutic opportunities for improving outcomes for obese breast cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=85019747545&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0178454

DO - 10.1371/journal.pone.0178454

M3 - Article

VL - 12

JO - PLoS ONE

T2 - PLoS ONE

JF - PLoS ONE

SN - 1932-6203

IS - 5

M1 - e0178454

ER -